Antibody engineering

Current Opinion in Structural Biology

Volumn 8, Issue 4, 1998, Pages 443-450

  Dall'Acqua, William ^a   Carter, Paul ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; ESCHERICHIA COLI; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RIBOSOME; RNA TRANSLATION;

EID: 0032143550     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(98)80121-8     Document Type: Article

References (69)

1. Carter P, Merchant AM. Engineering antibodies for imaging and therapy. Curr Opin Biotechnol. 8:1997;449-454.
2. Hudson PJ. Recombinant antibody fragments. Curr Opin Biotechnol. 9:1998;. in press.
3. Smithrud DB, Benkovic SJ. The state of antibody catalysis. Curr Opin Biotechnol. 8:1997;459-466.
4. Wade H, Scanlan TS. The structural and functional basis of antibody catalysis. Annu Rev Biophys Biomol Struct. 26:1997;461-493.
5. Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotech. 3:1997;83-105.
6. Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother. 45:1997;128-130.
7. Plückthun A, Krebber A, Krebber C, Horn U, Knüpfer U, Wenderoth R, Nieba L, Proba K, Riesenberg D. Producing antibodies in Escherichia coli: from PCR to fermentation. Hoogenboom H, McCafferty J, Chiswell D. Antibody Engineering: a Practical Approach. 1996;203-252 IRL Press, Oxford.
8. Rader C, Barbas CF. Phage display of combinatorial antibody libraries. Curr Opin Biotechnol. 8:1997;503-508.
9. Hoogenboom HR. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15:1997;62-70.
10. Brüggemann M, Taussig MJ. Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol. 8:1997;455-458.
11. Marasco WA. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther. 4:1997;11-15.
12. Spada S, Plückthun A. Selectively infective phage (SIP) technology: a novel method for in vivo selection of interacting protein-ligand pairs. Nat Med. 3:1997;694-696.
13. Spada S, Krebber C, Plückthun A. Selectively infective phages (SIP). Biol Chem. 378:1997;445-456.
14. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta. 1333:1997;C1-C6.
15. Goldman ER, Dall'Acqua W, Braden BC, Mariuzza RA. Analysis of binding interactions in an idiotope-antiidiotope protein-protein complex by double mutant cycles. of special interest Biochemistry. 36:1997;49-56 Mutational analysis of an idiotope-anti-idiotope complex demonstrated that most of the contact residues make a significant contribution to the energetics of binding. Double mutant analysis was used to quantitate the strength of hydrogen bonds and van der Waal's contacts, as well as probe the context dependence of these different interactions.
16. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 267:1995;383-386.
17. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA. 94:1997;7192-7197.
18. Trinh CH, Hemmington SD, Verhoeyen ME, Phillips SEV. Antibody fragment Fv4155 bound to two closely related steroid hormones: the structural basis of fine specificity. of special interest Structure. 5:1997;937-948 An elegant structural study that suggests a molecular basis for the fine specificity of an antibody fragment binding to two closely related steroids.
19. Winter G, Harris WJ. Humanized antibodies. Trends Pharmacol Sci. 14:1993;139-143.
20. Baca M, Presta L, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. of special interest J Biol Chem. 272:1997;10678-10684 A humanized antibody fragment was displayed on a phage and the framework region (FR) residues that were known to be important for the CDR conformation were partially randomized. A variant with a 125-fold enhancement in its antigen-binding affinity was isolated from the resulting library. This method is anticipated to be broadly applicable for the optimization of FR residues in humanized antibodies.
21. Holmes MA, Foote J. Structural consequences of humanizing an antibody. J Immunol. 158:1997;2192-2201.
22. Holmes MA, Buss TN, Foote J. Conformational correction mechanisms aiding antigen recognition by a humanized antibody. of special interest J Exp Med. 187:1998;479-485 A structural comparison was carried out between murine and humanized versions of an antibody bound to antigen. The grafted murine CDR loops can apparently reconfigure the human framework region (FR) into a conformation that is more like the murine FR. This self-correcting mechanism may have contributed, in part, to the wide success of humanization.
23. H domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs. Proteins. 29:1997;161-171.
24. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525.
25. Holliger PT, Prospero T, Winter G. 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 90:1993;6444-6448.
26. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/technology. 14:1996;192-196.
27. Zhu Z, Presta L, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6:1997;781-788.
28. FitzGerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng. 10:1997;1221-1225.
29. Holliger P, Wing M, Pound JD, Bohlen H, Winter G. Retargeting serum immunoglobulin with bispecific diabodies. of outstanding interest Nat Biotechnol. 15:1997;632-636 A bispecific diabody that binds IgG was demonstrated to support antibody secondary immune functions and have a significantly extended half-life in vivo. This work on endowing a diabody with IgG-like properties, together with the companion study on complement recruitment [30], expands the potential scope of diabodies for human therapy.
30. Kontermann RE, Wing MG, Winter G. Complement recruitment using bispecific diabodies. of special interest Nat Biotechnol. 15:1997;629-631 A bispecific diabody that binds C1q is shown to direct complement-mediated lysis of sheep red blood cells decorated with the second antigen.
31. L, are shown to form noncovalent trimers (called 'triabodies' in the companion paper, [32]) with three functional antigen-binding sites. The high apparent affinity of these trimers, resulting from their multivalency, together with their small size (~ 72 kDa), make them attractive candidates for radio-immuno-imaging and radio-immunotherapy.
32. Iliades P, Kortt AA, Hudson PJ. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409:1997;437-441.
33. L partner. This is a hitherto unknown source of structural and, presumably, functional diversity in the antigen-binding sites of antibodies.
34. Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hydridomas. Methods Enzymol. 121:1986;210-228.
35. H3 domains for heavy chain heterodimerization. Protein Eng. 9:1996;617-621.
36. H3 domains that promote the formation of stable heterodimers. Phage optimization provides a complementary and more comprehensive strategy for the rational design [35] and engineering of protein homodimers for heterodimerization.
37. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large nonimmunized phage display library. Nat Biotechnol. 14:1996;309-314.
38. Carter P, Rodrigues ML, Park JW, Zapata G. Preparation and uses of Fab' fragments from Escherichia coli. Hoogenboom H, McCafferty J, Chiswell D. Antibody Engineering: a Practical Approach. 1996;291-308 IRL Press, Oxford.
39. Medesan C, Matesoi D, Radu C, Ghetie V, Ward ES. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol. 158:1997;2211-2217.
40. 1 Fc were randomized and selected by phage display for binding to the neonatal Fc receptor, FcRn. Two mutant Fc molecules were identified that show higher affinity FcRn binding and a longer in vivo half-life than the wild-type Fc. This study demonstrates a role for FcRn in IgG homeostasis, as well as providing a strategy for manipulating the pharmacokinetic properties of IgG for clinical applications.
41. H: consequences for thermodynamic stability and folding. J Mol Biol. 265:1997;161-172.
42. Proba K, Worn A, Honneger A, Plückthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. of special interest J Mol Biol. 275:1998;245-253 Site-directed mutagenesis and DNA shuffling were combined with phage display in order to identify mutations that stabilize a scFv molecule lacking disulfide bonds. Such disulfide-free scFv are attractive for intracellular applications where the redox environment is problematic for disulfide-bond formation.
43. Schiweck W, Skerra A. The rational construction of an antibody against cystatin: lessons from the crystal structure of an artificial Fab fragment. J Mol Biol. 268:1997;934-951.
44. Rauffer-Bruyre N, Chatellier J, Weiss E, Van Regenmortel MH, Altschuh D. Cooperative effects of mutations in a recombinant Fab on the kinetics of antigen binding. Mol Immunol. 34:1997;165-173.
45. H domain of immunoglobulins. J Mol Biol. 275:1998;269-294.
46. L permutation. J Mol Biol. 268:1997;107-117.
47. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology. 10:1992;163-167.
48. Jung S, Plückthun A. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng. 10:1997;959-966.
49. Baca M, Scanlan TS, Stephenson RC, Wells JA. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding. Proc Natl Acad Sci USA. 94:1997;10063-10068.
50. Knappik A, Plückthun A. Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng. 8:1995;81-89.
51. Coia G, Ayres A, Lilley GG, Hudson PJ, Irving RA. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. of special interest Gene. 201:1997;203-209 The authors demonstrate a 10-fold increase in the apparent production levels of a scFv molecule by selection from a phage display library. This is one of the most promising methods for enhancing antibody fragment expression in E. coli. It is probably generally applicable and can be used in conjunction with the numerous available methods for diversifying phage libraries.
52. Tang Y, Jiang N, Parakh C, Hilvert D. Selection of linkers for a catalytic single-chain antibody using phage display technology. J Biol Chem. 271:1996;15682-15686.
53. Turner DJ, Ritter MA, George AJ. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods. 205:1997;43-54.
54. Nieba L, Honneger A, Krebber C, Plückthun A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 10:1997;435-444.
55. Burks EA, Chen G, Georgiou G, Iverson BL. In vitro scanning mutagenesis of an antibody binding pocket. of outstanding interest Proc Natl Acad Sci USA. 94:1997;412-417 The very rapid mutational analysis of an antibody is demonstrated using in vitro transcription and translation to circumvent time-consuming cloning and in vivo expression steps. This is a generic technology that is applicable to other proteins.
56. Ryabova LA, Desplancq D, Spirin AS, Plückthun A. Functional antibody production using cell-free translation: effects of protein disulfide isomerase and chaperones. of special interest Nat Biotechnol. 15:1997;79-84 A thorough study describing the optimization of the production of functional scFv molecules by in vitro transcription and translation.
57. Griffiths A, Williams SC, Hartley O, Tomlison IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al. Isolation of high-affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
58. d < 10 nM). This is a rapid and perhaps general route for generating highly specific agonist antibodies.
59. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. of outstanding interest Cancer Res. 58:1998;485-490 Tumor targeting was undertaken using scFv molecules with varying affinities (320 to 1 nM) for the tumor-associated antigen HER2/neu. The extent and specificity of tumor localization was greatly improved by increasing the antigen-binding affinity.
60. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. of outstanding interest Nat Biotechnol. 15:1997;1271-1275 The targeting of a scFv molecule to the tumor neovasculature-associated antigen oncofetal fibronectin was greatly improved using both affinity-matured and dimeric fragments. Imaging in real time was possible by IR photodetection using a fluorophore that was chemically coupled to the antibody fragment.
61. Krebber C, Spada S, Desplancq D, Krebber A, Ge L, Plückthun A. Selectively-infective phage (SIP): a mechanistic dissection of a novel in vivo selection for protein-ligand interactions. J Mol Biol. 268:1997;607-618.
62. Pedrazzi G, Schwesinger F, Honneger A, Krebber C, Plückthun A. Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology. of special interest FEBS Lett. 415:1997;289-293 A small and well-characterized library was used for the evaluation of the phage display technology SIP. This method apparently selects for many properties of the displayed molecule, including folding, stability and affinity.
63. Malmborg AC, Soderlind E, Frost L, Borrebaeck CAK. Selective phage infection mediated by epitope expression on F pilus. of special interest J Mol Biol. 273:1997;544-551 Genetically fusing a peptide to pilin prevents the infection of E. coli by wild-type M13 phages. Infection can be selectively restored by displaying on the phage a specific scFv that is capable of interacting with the pilin-peptide fusion. This work directly provides a foundation for identifying anti-peptide antibodies from scFv libraries.
64. Krebber C, Spada S, Desplancq D, Pluckthun A. Co-selection of cognate antibody-antigen pairs by selectively-infective phages. FEBS Lett. 377:1995;227-231.
65. Gao C, Lin CH, Lo CHL, Mao S, Wirsching P, Lerner RA, Janda KD: Making chemistry selectable by linking it to infectivity. Proc Natl Acad Sci USA 94: 11777-11782.
66. Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA. 91:1994;9022-9026.
67. Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. of outstanding interest Proc Natl Acad Sci USA. 94:1997;4937-4942 This is the first successful demonstration of ribosome display technology using proteins. This method, together with that in [68], is anticipated be generally useful for the identification and molecular evolution of proteins or peptides that bind targets of interest.
68. 5-fold were obtained in a single cycle.
69. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. of outstanding interest Nat Biotechnol. 16:1998;677-681 The production of human bispecific IgG (BsIgG) by co-expressing two different antibodies is inefficient due to unwanted pairings of the component heavy and light chains. A broadly applicable method was developed that overcomes these problems, enabling near quantitative formation and efficient recovery of human BsIgG. This technology substantially expands the clinical potential of human BsIgG.